{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06303115",
            "orgStudyIdInfo": {
                "id": "CSD231005 BoE"
            },
            "organization": {
                "fullName": "RAI Services Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "CSD231005 Nicotine Pouch Biomarkers of Exposure",
            "officialTitle": "A Multi Site, Open Label, Parallel Group Study to Assess Changes in Tobacco Related Biomarkers of Exposure Following Switching From Smoking of Combustible Cigarettes to Exclusive Use of Nicotine Pouches in Adult Smokers",
            "therapeuticArea": [
                "Other"
            ],
            "study": "nicotine-pouch-biomarkers-of-exposure"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-15",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-04",
            "studyFirstSubmitQcDate": "2024-03-04",
            "studyFirstPostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "RAI Services Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to use of nicotine Pouch investigational products (IPs) compared to continued usual brand (UB) cigarette smoking or smoking abstinence."
        },
        "conditionsModule": {
            "conditions": [
                "Tobacco Use",
                "Smoking"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Nicotine Pouch P1312914, 4 mg nicotine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects will be switched to exclusive use of their assigned pouch flavor and strength.",
                    "interventionNames": [
                        "Other: Nicotine Pouch P1312914, 4 mg nicotine"
                    ]
                },
                {
                    "label": "Nicotine Pouch P1312915, 8 mg nicotine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects will be switched to exclusive use of their assigned pouch flavor and strength.",
                    "interventionNames": [
                        "Other: Nicotine Pouch P1312915, 8 mg nicotine"
                    ]
                },
                {
                    "label": "Nicotine Pouch P1013215, 8 mg nicotine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects will be switched to exclusive use of their assigned pouch flavor and strength.",
                    "interventionNames": [
                        "Other: Nicotine Pouch P1013215, 8 mg nicotine"
                    ]
                },
                {
                    "label": "Nicotine Pouch P1013218, 10 mg nicotine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects will be switched to exclusive use of their assigned pouch flavor and strength.",
                    "interventionNames": [
                        "Other: Nicotine Pouch P1013218, 10 mg nicotine"
                    ]
                },
                {
                    "label": "Nicotine Pouch P1012919, 12 mg nicotine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects will be switched to exclusive use of their assigned pouch flavor and strength.",
                    "interventionNames": [
                        "Other: Nicotine Pouch P1012919, 12 mg nicotine"
                    ]
                },
                {
                    "label": "Smoking Abstinence",
                    "type": "OTHER",
                    "description": "Subjects will not use any tobacco or nicotine containing products.",
                    "interventionNames": [
                        "Other: Smoking Abstinence"
                    ]
                },
                {
                    "label": "Continued UB cigarette smoking",
                    "type": "OTHER",
                    "description": "Subjects will continue use of their Usual Brand Cigarettes.",
                    "interventionNames": [
                        "Other: Continued UB cigarette smoking"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Nicotine Pouch P1312914, 4 mg nicotine",
                    "description": "P1312914 pouch product",
                    "armGroupLabels": [
                        "Nicotine Pouch P1312914, 4 mg nicotine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Nicotine Pouch P1312915, 8 mg nicotine",
                    "description": "P1312915 pouch product",
                    "armGroupLabels": [
                        "Nicotine Pouch P1312915, 8 mg nicotine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Nicotine Pouch P1013215, 8 mg nicotine",
                    "description": "P1013215 pouch product",
                    "armGroupLabels": [
                        "Nicotine Pouch P1013215, 8 mg nicotine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Nicotine Pouch P1013218, 10 mg nicotine",
                    "description": "P1013218 pouch product",
                    "armGroupLabels": [
                        "Nicotine Pouch P1013218, 10 mg nicotine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Nicotine Pouch P1012919, 12 mg nicotine",
                    "description": "P1012919 pouch product",
                    "armGroupLabels": [
                        "Nicotine Pouch P1012919, 12 mg nicotine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Smoking Abstinence",
                    "description": "No tobacco/nicotine",
                    "armGroupLabels": [
                        "Smoking Abstinence"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Continued UB cigarette smoking",
                    "description": "Usual Brand Cigarette",
                    "armGroupLabels": [
                        "Continued UB cigarette smoking"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "4(methylnitrosamino)1(3pyridyl)1butanol [NNAL] + glucuronides [Total NNAL]",
                    "timeFrame": "24 hour"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "4Aminobiphenyl [4ABP]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "1Aminonaphthalene [1AN]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "2Aminonaphthalene [2AN]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "2Cyanoethyl mercapturic acid [CEMA]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "3Hydroxypropyl mercapturic acid [3HPMA]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "3Hydroxy1methylpropylmercapturic acid [HMPMA]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "3hydroxybenzo[a]pyrene [3-OH-B[a]P]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "1hydroxypyrene [1OHP]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "Monohydroxybutyl mercapturic acid [MHBMA]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "Nnitrosonornicotine [NNN] + glucuronides [Total NNN]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "SPhenyl mercapturic acid [SPMA]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "Total nicotine equivalents (molar sum of nicotine, cotinine, 3hydroxycotinine and their glucuronides) [TNneq]",
                    "timeFrame": "24 hour"
                },
                {
                    "measure": "Carboxyhemoglobin [COHb]",
                    "timeFrame": "12 hour"
                },
                {
                    "measure": "Nnitrosonornicotine [NNN] + glucuronides [Total NNN]",
                    "timeFrame": "12 hour"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nAble to read, understand, and be willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.\n\nGenerally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n\nSmokes combustible, filtered, nonmenthol or menthol cigarettes, 83 mm to 100 mm in length.\n\nSmokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke for at least six months prior to Screening. Brief periods of abstinence due to illness, a quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the PI.\n\nSelf-reports that cigarettes are their primary tobacco- or nicotine-containing product use within 30 days of Screening. (Note: occasional use of other tobacco- or nicotine-containing products may be acceptable in consultation with the Sponsor);\n\nAgrees to use assigned IP throughout the study period.\n\nExpired breath carbon monoxide (ECO) level \u2265 10 ppm and \u2264 100 ppm at Screening and at CheckIn on Day 2.\n\nPositive urine cotinine test at Screening.\n\nResponse at Screening to the Fagerstr\u00f6m Test for Nicotine Dependence (FTND) question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"630 minutes.\" (Heatherton, Kozlowski, Frecker, \\& Fagerstrom, 1991).\n\nWilling to switch from current UB cigarette to either nicotine Pouch IP, or abstain from smoking, for approximately 5 days during in-clinic confinement;\n\nFemales must be willing to use a form of contraception acceptable to the PI from the time of signing the informed consent until the End of Study (EOS).\n\nExamples of acceptable means of birth control are, but not limited to:\n\n1. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy);\n2. Established use of oral, implantable, injectable or transdermal methods of contraception associated with inhibition of ovulation (see Section 6.10 regarding the use of hormonal methods of contraception in females aged \u2265 35);\n3. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide;\n4. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena) (see Section 6.10 regarding the use of hormonal methods of contraception in females aged \u2265 35);\n5. Vasectomized partner;\n6. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and\n7. Post-menopausal and not on hormone replacement therapy.\n\nMales must be willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they had undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children.\n\nWilling to refrain from consuming cruciferous vegetables and grilled, smoked, fried or barbequed food, and to avoid being in the presence of the cooking of these foods. Subjects should also be willing to refrain from consuming cured sandwich meats, bacon, salami, and sausages 48 hours prior to CheckIn on Day 2.\n\nAgrees to inclinic confinement of 8 days (7 nights).\n\nExclusion Criteria:\n\nThe presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the subject unsuitable to participate in this clinical study.\n\nHistory, presence of, or clinical laboratory test results indicating diabetes. Fasting plasma glucose \\> 126 mg/dL (7 mmol/L) is exclusionary. One recheck may be performed for fasting plasma glucose values \\> 126 mg/dL but \\< 200 mg/dL.\n\nScheduled treatment for asthma currently or within the past 12 consecutive months prior to Screening. As needed treatment, such as inhalers, may be included at the PI's discretion, pending approval from the Medical Monitor.\n\nUse of any medications that interfere with the cyclooxygenase pathway (e.g., antiinflammatoryanti-inflammatory drugs such as aspirin and ibuprofen) 14 days prior to CheckIn on Day 2.\n\nUse of medications or substances (other than nicotine) known to be strong inducers or inhibitors of cytochrome P450 (CYP) enzymes within 14 days or 5 halflives of the medication or substances (whichever is longer) prior to CheckIn on Day 2.\n\nHistory or presence of bleeding or clotting disorders.\n\nAny history of cancer, except for primary cancers of the skin, such as localized basal cell/squamous cell carcinoma, that have been surgically and/or cryogenically removed.\n\nSystolic blood pressure (BP) of \\> 160 mmHg or a diastolic BP of \\> 95 mmHg, measured after being seated for 5 minutes at Screening and CheckIn on Day 2.\n\nBody Mass Index (BMI) \\< 18.0 or \\>40.0 kg/m2 (weight of \u2264 110 pounds) at Screening.\n\nHemoglobin level \\< 12.5 g/dL for females or \\<13.0 g/dL for males at Screening.\n\nFemales who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n\nA positive urine drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening or CheckIn on Day 2.\n\nPositive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBbsAg), or hepatitis C virus (HCV).\n\nUse of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix\u00ae), bupropion (Wellbutrin\u00ae, Zyban\u00ae), or lobelia extract within (\u2264) 30 days prior to signing of the ICF.\n\nPostpones a decision to quit using tobacco or nicotinecontaining products to participate in this study or has made a previous quit attempt within (\u2264) 30 days prior to the signing of the ICF.\n\nAny daily use of aspirin (\u2265 325 mg/day) or anticoagulants (e.g., Clopidogrel \\[Plavix\u00ae\\], Warfarin \\[Coumadin\u00ae, Jantoven\u00ae\\]).\n\nIndividuals \u2265 35 years of age currently using systemic, estrogencontaining contraception or hormone replacement therapy.\n\nWhole blood donation within 8 weeks (\u2264 56 days) prior to the signing of the ICF.\n\nNOTE: Subjects will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n\nPlasma donation within (\u2264) 7 days prior to the ICF. NOTE: Subjects will be advised against scheduling a plasma donation for at least 7 days following study completion.\n\nEmployed by a tobacco or nicotine company, the study site, or handles tobacco or nicotinecontaining products as part of their job.\n\nParticipation in another clinical trial within (\u2264) 30 days prior to the signing of the ICF. The 30day window for each subject will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n\nDrinks more than 21 servings of alcoholic beverages per week.\n\nHas a positive alcohol result at Screening or CheckIn on Day 2.\n\nDetermined by the PI to be inappropriate for this study.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "John Darnell",
                    "role": "CONTACT",
                    "phone": "3367410386",
                    "email": "csd201204actualusestudyemail@rjrt.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Brian Keyser, PhD",
                    "affiliation": "Reynolds American",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Pillar Bentonville",
                    "city": "Bentonville",
                    "state": "Arkansas",
                    "zip": "72712",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.37285,
                        "lon": -94.20882
                    }
                },
                {
                    "facility": "AMR Lexington",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40509",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                },
                {
                    "facility": "QPS Missouri",
                    "city": "Springfield",
                    "state": "Missouri",
                    "zip": "65802",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.21533,
                        "lon": -93.29824
                    }
                },
                {
                    "facility": "AMR Knoxville",
                    "city": "Knoxville",
                    "state": "Tennessee",
                    "zip": "37920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "William Smith, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.96064,
                        "lon": -83.92074
                    }
                },
                {
                    "facility": "Pillar Richardson",
                    "city": "Richardson",
                    "state": "Texas",
                    "zip": "75080",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.94818,
                        "lon": -96.72972
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009538",
                    "term": "Nicotine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005731",
                    "term": "Ganglionic Stimulants"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018722",
                    "term": "Nicotinic Agonists"
                },
                {
                    "id": "D000018679",
                    "term": "Cholinergic Agonists"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12478",
                    "name": "Nicotine",
                    "asFound": "Assess",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4029",
                    "name": "Central Nervous System Stimulants",
                    "relevance": "LOW"
                },
                {
                    "id": "M20796",
                    "name": "Nicotinic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                }
            ]
        }
    },
    "hasResults": false
}